Vera Therapeutics Inc - Class A — Liquidità Trimestrale (NASDAQ:VERA) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 655.68 M610.17 M578.53 M517.5 M734.73 M Totale passività 78.53 M75.17 M110.25 M118.62 M130.21 M Patrimonio netto totale 577.15 M535 M468.28 M398.88 M604.52 M Totale passività e patrimonio netto 655.68 M610.17 M578.53 M517.5 M734.73 M Debito totale 54.64 M54.47 M77.55 M77.22 M77.31 M Indebitamento netto -586.21 M-535.37 M-479.27 M-420.17 M-637.28 M

Notizie

Vera Therapeutics nomina Jane Wright-Mitchell direttrice legale

Wolfe Research alza il rating di Vera Therapeutics sulla base della valutazione

Wolfe Research upgrades Vera Therapeutics stock rating on valuation

BofA Securities conferma rating Buy su Vera Therapeutics

Vera Therapeutics stock rating reaffirmed at Buy by BofA Securities

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vera Therapeutics adds Christopher Hite to board of directors

3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026 - TipRanks.com

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

VeraDermics is said to draw IPO anchor order from Eli Lilly - Bloomberg

Vera Therapeutics promuove Matt Skelton a direttore commerciale

Vera Therapeutics promotes Matt Skelton to chief commercial officer